177 related articles for article (PubMed ID: 30032164)
1. miR-140-5p inhibits the proliferation and enhances the efficacy of doxorubicin to breast cancer stem cells by targeting Wnt1.
Wu D; Zhang J; Lu Y; Bo S; Li L; Wang L; Zhang Q; Mao J
Cancer Gene Ther; 2019 Mar; 26(3-4):74-82. PubMed ID: 30032164
[TBL] [Abstract][Full Text] [Related]
2. Effect of miR-7 on resistance of breast cancer cells to adriamycin via regulating EGFR/PI3K signaling pathway.
Huang Q; Wu YY; Xing SJ; Yu ZW
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5285-5292. PubMed ID: 31298380
[TBL] [Abstract][Full Text] [Related]
3. MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2).
Jiao X; Zhao L; Ma M; Bai X; He M; Yan Y; Wang Y; Chen Q; Zhao X; Zhou M; Cui Z; Zheng Z; Wang E; Wei M
Breast Cancer Res Treat; 2013 Jun; 139(3):717-30. PubMed ID: 23780685
[TBL] [Abstract][Full Text] [Related]
4. miRNA-205 targets VEGFA and FGF2 and regulates resistance to chemotherapeutics in breast cancer.
Hu Y; Qiu Y; Yagüe E; Ji W; Liu J; Zhang J
Cell Death Dis; 2016 Jun; 7(6):e2291. PubMed ID: 27362808
[TBL] [Abstract][Full Text] [Related]
5. Ultrasound reverses chemoresistance in breast cancer stem cell like cells by altering ABCG2 expression.
Guo L; Zheng P; Fan H; Wang H; Xu W; Zhou W
Biosci Rep; 2017 Dec; 37(6):. PubMed ID: 28935760
[TBL] [Abstract][Full Text] [Related]
6. miRNA-192-5p impacts the sensitivity of breast cancer cells to doxorubicin via targeting peptidylprolyl isomerase A.
Zhang Y; He Y; Lu LL; Zhou ZY; Wan NB; Li GP; He X; Deng HW
Kaohsiung J Med Sci; 2019 Jan; 35(1):17-23. PubMed ID: 30844143
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-664-5p promotes myoblast proliferation and inhibits myoblast differentiation by targeting serum response factor and
Cai R; Qimuge N; Ma M; Wang Y; Tang G; Zhang Q; Sun Y; Chen X; Yu T; Dong W; Yang G; Pang W
J Biol Chem; 2018 Dec; 293(50):19177-19190. PubMed ID: 30323063
[TBL] [Abstract][Full Text] [Related]
8. LncRNA HOTTIP facilitates the stemness of breast cancer via regulation of miR-148a-3p/WNT1 pathway.
Han L; Yan Y; Zhao L; Liu Y; Lv X; Zhang L; Zhao Y; Zhao H; He M; Wei M
J Cell Mol Med; 2020 Jun; 24(11):6242-6252. PubMed ID: 32307830
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-132 and microRNA-212 mediate doxorubicin resistance by down-regulating the PTEN-AKT/NF-κB signaling pathway in breast cancer.
Xie M; Fu Z; Cao J; Liu Y; Wu J; Li Q; Chen Y
Biomed Pharmacother; 2018 Jun; 102():286-294. PubMed ID: 29567542
[TBL] [Abstract][Full Text] [Related]
10. MiR-124 reversed the doxorubicin resistance of breast cancer stem cells through STAT3/HIF-1 signaling pathways.
Liu C; Xing H; Guo C; Yang Z; Wang Y; Wang Y
Cell Cycle; 2019 Sep; 18(18):2215-2227. PubMed ID: 31286834
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-574 enhances doxorubicin resistance through down-regulating SMAD4 in breast cancer cells.
Sun FD; Wang PC; Luan RL; Zou SH; Du X
Eur Rev Med Pharmacol Sci; 2018 Mar; 22(5):1342-1350. PubMed ID: 29565492
[TBL] [Abstract][Full Text] [Related]
12. miR-135b-5p enhances doxorubicin-sensitivity of breast cancer cells through targeting anterior gradient 2.
Zhang Y; Xia F; Zhang F; Cui Y; Wang Q; Liu H; Wu Y
J Exp Clin Cancer Res; 2019 Jan; 38(1):26. PubMed ID: 30665445
[TBL] [Abstract][Full Text] [Related]
13. miR-520b Inhibits IGF-1R to Increase Doxorubicin Sensitivity and Promote Cell Apoptosis in Breast Cancer.
Zhang H; Zheng XD; Zeng XH; Li L; Zhou Q
Yakugaku Zasshi; 2021 Mar; 141(3):415-426. PubMed ID: 33116033
[TBL] [Abstract][Full Text] [Related]
14. MiR-26a-5p Inhibits Cell Proliferation and Enhances Doxorubicin Sensitivity in HCC Cells via Targeting AURKA.
Yuan YL; Yu H; Mu SM; Dong YD; Li Y
Technol Cancer Res Treat; 2019 Jan; 18():1533033819851833. PubMed ID: 31570091
[TBL] [Abstract][Full Text] [Related]
15. Curcumol enhances the sensitivity of doxorubicin in triple-negative breast cancer via regulating the miR-181b-2-3p-ABCC3 axis.
Zeng C; Fan D; Xu Y; Li X; Yuan J; Yang Q; Zhou X; Lu J; Zhang C; Han J; Gu J; Gao Y; Sun L; Wang S
Biochem Pharmacol; 2020 Apr; 174():113795. PubMed ID: 31926937
[TBL] [Abstract][Full Text] [Related]
16. microRNA-129-5p suppresses Adriamycin resistance in breast cancer by targeting SOX2.
Zeng H; Wang L; Wang J; Chen T; Li H; Zhang K; Chen J; Zhen S; Tuluhong D; Li J; Wang S
Arch Biochem Biophys; 2018 Aug; 651():52-60. PubMed ID: 29802821
[TBL] [Abstract][Full Text] [Related]
17. P53-miR-191-
Sharma S; Nagpal N; Ghosh PC; Kulshreshtha R
RNA; 2017 Aug; 23(8):1237-1246. PubMed ID: 28450532
[TBL] [Abstract][Full Text] [Related]
18. miR-381 overcomes cisplatin resistance in breast cancer by targeting MDR1.
Yi D; Xu L; Wang R; Lu X; Sang J
Cell Biol Int; 2019 Jan; 43(1):12-21. PubMed ID: 30444043
[TBL] [Abstract][Full Text] [Related]
19. MiR-139-5p inhibits the biological function of breast cancer cells by targeting Notch1 and mediates chemosensitivity to docetaxel.
Zhang HD; Sun DW; Mao L; Zhang J; Jiang LH; Li J; Wu Y; Ji H; Chen W; Wang J; Ma R; Cao HX; Wu JZ; Tang JH
Biochem Biophys Res Commun; 2015 Oct; 465(4):702-13. PubMed ID: 26299922
[TBL] [Abstract][Full Text] [Related]
20. Long non-coding RNA FTH1P3 activates paclitaxel resistance in breast cancer through miR-206/ABCB1.
Wang R; Zhang T; Yang Z; Jiang C; Seng J
J Cell Mol Med; 2018 Sep; 22(9):4068-4075. PubMed ID: 29971911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
